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Background: Although typically a late feature of gout, tophi may present early in the course of disease. The aim of
this study was to identify factors associated with the presence of early tophaceous disease.
Methods: People with gout for <10 years were prospectively recruited, and had a comprehensive clinical
assessment including examination for subcutaneous tophi. The clinical factors independently associated with the
presence and number of tophi were analyzed using regression models.
Results: Of the 290 participants, there were 47 (16.2%) with clinically apparent tophi. In univariate analysis, those
with tophi were older, were more frequently taking diuretics and colchicine prophylaxis, and had lower creatinine
clearance. The association between the presence of tophi and creatinine clearance was strongest in those with
creatinine clearance ≤30 ml/min. In logistic regression analysis, creatinine clearance ≤30 ml/min was associated
with the presence of tophi, even after adjusting for ethnicity, corticosteroid use, colchicine use and diuretic use
(multivariate adjusted odds ratio 7.0, p = 0.005). Participants with tophi reported higher frequency of gout flares,
pain scores, patient global assessment scores, and HAQ scores.
Conclusions: The presence of tophi is associated with more symptomatic disease in people with gout
for <10 years. Creatinine clearance is independently associated with early presentation of subcutaneous tophi.
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The tophus is the pathognomic feature of chronic gout,
and represents a chronic foreign-body granulomatous re-
sponse to monosodium urate (MSU) crystal deposits [1].
In untreated gout, development of subcutaneous tophi is
typically a late feature of disease, occurring more than
10 years after development of gout flares [2,3]. Tophi are
more frequently observed in people with prolonged dis-
ease duration, advanced age, diuretic use, corticosteroid
use and solid organ transplantation [3-6]. Gouty tophi
have major clinical relevance, as they contribute to mus-
culoskeletal disability and reduced health-related quality
of life [7,8]. These lesions are also implicated in joint* Correspondence: n.dalbeth@auckland.ac.nz
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stated.damage in gout, and are associated with increased risk of
mortality in people with gout [9,10].
Although these lesions are typically a late feature of
gout, gouty tophi occasionally present early in the course
of disease, either as the initial manifestation of gout or
within a few years of first gout flare. The factors asso-
ciated with early presentation of subcutaneous tophi in
people with gout have not been reported. The aim of
this analysis was to identify factors associated with the
presence of early tophaceous disease.
Methods
Participants were prospectively recruited by community
advertising and through primary and secondary care clinics
in Auckland and Wellington, New Zealand. Key inclusion
criteria were: classification of gout as defined by Wallace
[11], and first attack of gout and/or tophus within the
last 10 years. The New Zealand Multiregional Ethicsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical features of participants with and without tophi
Variable No tophi (n = 243) Tophi (n = 47) p
Age, years 57.8 (14.5) 64.1 (14.0) 0.006
Male sex, n (%) 170 (70.0%) 33 (70%) 1.0
Ethnicity
Caucasian/other, n (%) 182 (74.8%) 36 (77%) 1.0
Maori or pacific, n (%) 61 (25.2%) 11 (23%) 1.0
Disease duration, years 5.1 (3.8) 5.8 (3.2) 0.22
Cardiovascular events, n (%) 76 (31.3%) 20 (43%) 0.18
Type 2 diabetes, n (%) 29 (12%) 8 (17%) 0.34
Hypertension, n (%) 98 (40.3%) 18 (38%) 0.87
Kidney stones, n (%) 17 (7.0%) 5 (11%) 0.37
Diuretic use, n (%) 61 (25.1%) 22 (47%) 0.004
Colchicine use 70 (28.8%) 21 (45%) 0.039
Non-steroidal anti-inflammatory drug use 50 (20.5%) 8 (17%) 0.79
Allopurinol use, n (%) 147 (60.5%) 26 (55%) 0.52
Allopurinol dose, mg/day 215 (92) 213 (116) 0.93
Corticosteroid use, n (%) 29 (11.9%) 10 (21%) 0.10
Low dose aspirin use, n (%) 62 (25.5%) 15 (32%) 0.37
Adherence score* 40.9 (6.2) 40.9 (5.9) 1.0
Body mass index, kg/m2 31.3 (6.9) 30.0 (6.5) 0.23
Systolic blood pressure, mmHg 138 (22) 139 (23) 0.68
Creatinine clearance, mL/min 72.1 (28.6) 56.3 (27.4) 0.001
C-reactive protein, mg/L 5.3 (11.9) 8.0 (15.0) 0.17
Serum urate, mmol/L 0.40 (0.13) 0.43 (0.11) 0.25
Gout flare frequency, per 3 months 1.8 (5.9) 5.4 (18.2) 0.01
Tophus count 0 (0) 3.1 (3.4) <0.001
Tender joint count (/68) 1.6 (3.9) 5.8 (8.7) <0.001
Swollen joint count (/66) 0.6 (1.8) 3.3 (7.1) <0.001
HAQ-II 0.43 (0.55) 0.77 (0.73) 0.001
Patient global assessment, mm 21.9 (23.1) 33.7 (26.4) 0.002
Pain visual analogue scale, mm 15.9 (24.2) 24.9 (25.9) 0.021
*for those on urate-lowering therapy.
Unless specified otherwise, data are presented as mean (SD).
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vided written informed consent.
At a study visit, the following data were recorded:
demographic data (age, gender, ethnicity), gout history
(confirmation of diagnosis, disease duration, frequency
of gout flares, days off work due to gout in the preceding
three months, gout treatments), medical history and con-
comitant medications including diuretics, examination
(tender (68) and swollen (66) joint counts and subcuta-
neous tophus count), questionnaires (a 9-item self re-
port adherence questionnaire based on the Medication
Adherence Report Scale [12] to assess adherence to urate
lowering therapy [13], Health Assessment Questionnaire
(HAQ)-II [14], patient global assessment of gout severityvisual analogue scale (100 mm) and pain visual analogue
scale (100 mm)), laboratory tests (serum urate, creatinine
and C-reactive protein). Creatinine clearance was calcu-
lated using the Cockcroft-Gault equation [15]. Estimated
glomerular filtration rate (eGFR) was determined using
the Modification of Diet in Renal Disease formula [16].
The presence and number of subcutaneous tophi were
recorded by one of two clinical research assistants with
extensive experience in the assessment and measurement
of tophi. Flare frequency was self-reported as the number
of gout flares in the preceding three months. Disease dur-
ation was reported by the patient and was defined as the
time from the first clinical manifestation of gout (either
flare or tophus).
Table 2 Correlations between tophus count and clinical
features in all participants (n = 290)
Variable R p
Age 0.15 0.01
Disease duration 0.10 0.09
Body mass index −0.10 0.10
Systolic blood pressure 0.01 0.83
Creatinine clearance −0.22 <0.001
C-reactive protein 0.10 0.11
Serum urate 0.08 0.19
Gout flare frequency 0.06 0.33
Tender joint count 0.26 <0.001
Swollen joint count 0.23 <0.001
HAQ-II 0.18 0.003
Patient global assessment 0.20 0.001
Pain visual analogue scale 0.16 0.006
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Means with standard deviations (SD) and percentages were
used to describe the clinical characteristics of participants.
Differences between participants with and without tophi
were analyzed using chi squared analysis and t tests. Spear-
man’s correlations were used to determine the relationship
between tophus count and other clinical variables. Logistic
regression was used to determine the independent clinical
variables associated with the presence of tophi. Poisson re-
gression was used to determine the independent clinical
variables associated with the subcutaneous tophus count.
Clinical factors with p < 0.15 in the univariate analysis for
presence of tophi were included in the regression models
(in addition to ethnicity). The key variables of interest were
pre-specified as the presence of tophi and the number of
tophi. Creatinine clearance was pre-specified as the mea-
sure of renal function in this analysis. All tests were two
tailed and P < 0.05 was considered statistically significant.
Results
We recruited 290 people with gout for <10 years into the
study. Of these, there were 47 (16.2%) participants with
clinically apparent tophi. In participants with tophaceous




(n = 243), n (%)
Tophi
(n = 47), n (%)
Unadjusted odd
ratio (95% CI)
>90 63 (25.9%) 4 (9%) 1.0 (ref)
>60-90 90 (37.0%) 14 (30%) 2.4 (0.8-7.8)
>30-60 74 (30.5%) 19 (40%) 4.1 (1.3-12.7)
0-30 16 (6.6%) 10 (21%) 9.7 (2.7-35.0)
*adjusted for ethnicity, corticosteroid use, diuretic use and colchicine use.the mean (SD) disease duration was 5.8 (3.2) years. The
clinical features of those with and without tophi are shown
in Table 1. In univariate analysis, those with tophi were
older, were more frequently taking diuretics and colchi-
cine, and had lower creatinine clearance.
Physical examination showed more swollen and ten-
der joints in those with tophi (Table 1). Participants
with tophi reported higher frequency of gout flares, pain
scores, patient global assessment scores, and HAQ scores.
After adjusting for sex, age and ethnicity, the relationship
persisted between the presence of tophi and HAQ (p =
0.002), patient global assessment (p = 0.002), and pain vi-
sual analogue scale (p = 0.02).
In the entire group of participants, the number of tophi
correlated with age, creatinine clearance, but not with body
mass index or serum urate concentration (Table 2). The
number of tophi also correlated with swollen and tender
joint counts, patient global assessment, pain visual ana-
logue, and HAQ scores. Gout flare frequency and C-
reactive protein did not correlate with the number of tophi.
The association between the presence of tophi and cre-
atinine clearance was strongest in those with creatinine
clearance ≤30 ml/min (Table 3). In logistic regression ana-
lysis, creatinine clearance ≤30 ml/min was associated with
the presence of tophi, even after adjusting for ethnicity,
corticosteroid use, colchicine use and diuretic use (multi-
variate adjusted odds ratio 7.0, p = 0.005). After adjusting
for creatinine clearance, age and diuretic use were not as-
sociated with the presence of tophi (adjusted p = 0.64 and
0.10 respectively). The relationship between renal function
and the presence of tophi was confirmed using eGFR as
an additional measure of kidney function. In this analysis,
eGFR of 30–59 ml/min/1.73 m2 was associated with the
presence of tophi (unadjusted OR (95% CI) 3.2 (1.3-7.7),
p = 0.009), with a similar trend for eGFR < 30 ml/min/
1.73 m2 (OR (95% CI) 3.8 (0.94-15.1), p = 0.06).
In Poisson regression analysis, there was a strong rela-
tionship between creatinine clearance bands with the to-
phus count, even after adjusting for ethnicity, corticosteroid
use, colchicine use and diuretic use (Table 4). When ana-
lyzing those with at least one tophus (n = 47), creatinine
clearance ≤30 ml/min was associated with tophus count
(unadjusted relative risk estimate 2.3 (1.02-5.1), p =







- 1.0 (ref) -
0.13 2.2 (0.7-7.3) 0.19
0.015 3.0 (0.9-10.0) 0.07
0.001 7.0 (1.8-27.6) 0.005




risk estimate (95% CI)
Unadjusted P Multivariate* adjusted
relative risk estimate (95% CI)
Multivariate*
adjusted P
>90 1.0 (ref) - 1.0 (ref) -
>60-90 2.6 (1.1-5.9) 0.025 2.5 (1.1-5.8) 0.031
>30-60 7.2 (3.3-15.7) <0.001 6.1 (2.8-13.7) <0.001
0-30 14.7 (6.6-32.9) <0.001 12.0 (5.2-27.7) <0.001
*adjusted for ethnicity, corticosteroid use, diuretic use and colchicine use.
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were associated with the number of tophi (unadjusted rela-
tive risk estimate (95% CI) 7.2 (4.0-12.9) and 5.4 (2.4-12.1)
respectively, p < 0.001 for both).
Discussion
In this study, just over 15% of participants with gout for
less than 10 years had tophaceous disease. Creatinine
clearance was the major factor independently associated
with early presentation with tophi. Although other factors
such as diuretic use and older age were associated with
presence of tophi in univariate analysis, these factors were
not independently associated with early tophaceous di-
sease when creatinine clearance was included in the regres-
sion models. These data raise the possibility that kidney
disease may play a role in the development of tophaceous
disease, or conversely that kidney deposition of MSU crys-
tals causing renal impairment is more common in patients
with tophaceous disease.
It is of interest that variables such as ethnicity, sex and
body mass index were not associated with early pre-
sentation with tophi. In addition, this study did not show
a relationship between presence of tophi and disease du-
ration, serum urate concentration, use of urate-lowering
therapy, dose of urate-lowering therapy or compliance to
urate-lowering therapy. Using the current study design,
we cannot exclude the possibility that the duration of
hyperuricaemia prior to development of gout or treatment
prior to study entry may have contributed to the risk of
developing tophi. Although these patients had relatively
early disease, the cross-sectional nature of this study does
not allow us to determine the direction of the relationship
between tophaceous disease and renal impairment; that is,
whether patients who were inadequately treated developed
tophi and gout-related kidney disease, or whether kidney
disease at presentation contributed to development of to-
phi, even in the presence of adequate gout treatment. It
seems likely that the presence of kidney disease would lead
to lower excretion of uric acid, and potentially greater urate
pool, which may not be entirely reflected by serum urate
concentrations [17]. It is also conceivable that chronic kid-
ney disease could promote development of tophi through
mechanisms in addition to increased urate pool. Potential
mechanisms might include acceleration of MSU crystalnucleation or growth, or altered immune responses to
MSU crystals [18].
Our data provide further evidence that the presence of
gouty tophi is associated with important functional con-
sequences for people with gout. We have observed that
participants with tophi have more evidence of joint in-
flammation, greater pain scores, and more activity limita-
tion, despite higher use of colchicine prophylaxis. These
findings are consistent with other studies of people with
gout [7,8], and emphasize the need to carefully examine
for tophi even in early disease, and treat intensively in the
context of tophaceous disease [19,20]. A concerning ob-
servation of this study was the low use of urate-lowering
therapy and poor control of serum urate, particularly in
those with tophi, which is a recognized indication for
pharmacological urate-lowering therapy [19]. These find-
ings are consistent with many other studies of gout man-
agement worldwide [21,22]. Our findings support the
importance of further patient and practitioner education
about the need to examine for tophi (even in patients
with early disease), and initiate effective urate-lowering
therapy to prevent tophi and dissolve these lesions once
they occur.
We acknowledge the potential limitations of this study.
Tophi were not microscopically proven, and it is possible
that some designated tophi represented other lesions. This
analysis has focused on subcutaneous tophi, without the
use of advanced imaging methods such as ultrasound or
dual energy computed tomography, which may detect
many more tophi than are clinically apparent [23].
Furthermore, assessment of joint inflammation, particu-
larly the causes of joint swelling, can be difficult in people
with gout, where tophi, osteoarthritis, and synovitis may
co-exist [24]. These issues are consistent with the reality
of usual clinical practice. In this study, disease duration
was defined as the time from the first clinical manifest-
ation of gout (either flare or tophus). Estimation of disease
duration may be difficult in gout, especially since tophi
may be occur before the onset of flares and may be un-
detected by both the individual and healthcare profes-
sionals. However, the definition used is consistent with
virtually all studies of gout, and is likely to be reliable,
noting the typically severe symptoms of pain and disability
associated with an acute gout flare.
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Tophaceous disease occurs early in the course of gout
in approximately 15% people. The presence of tophi is
strongly associated with features of chronic joint in-
flammation, pain and activity limitation. Creatinine clea-
rance is independently associated with the presence of
subcutaneous tophi in people with recent onset gout. Pro-
spective longitudinal studies are needed to address the
relative importance of chronic kidney disease, urate bur-
den and other risk factors in the development of tophi in
people with gout.
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